MTEM

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted biologic therapeutics. Its drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragment (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized Shiga-like toxin-A subunit (SLTA) and a class I antigen derived from the human cytomegalovirus (HCMV). pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 focuses on targeting CD38. CD38 is a single-chain type II transmembrane glycoprotein that is expressed by a variety of hematologic cells in an activation- and differentiation-dependent manner.